
Covance Not Cooling...


| Price and Volume | |
|---|---|
| Recent Price | 4.74 |
| 52 Week High | 11.44 |
| 52 Week Low | 4.41 |
| Avg. Daily Vol. (Mil) | 0.88 |
| Beta (3 year) | 0.95 |
| Share Related Items | |
| Mkt Cap (Mil) | 413.05 |
| Shares Out (Mil) | 87.14 |
| Float (Mil) | 64.17 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 29.00 |
| Current Ratio | 30.10 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 275.36 |
| Price/Book | 1.56 |
| Price/Cash Flow | -4.20 |
| Per Share Data | |
| Earnings | -1.29 |
| Sales | 0.02 |
| Book Value | 3.04 |
| Cash Flow | -1.13 |
| Business Summary | |
|---|---|
| Rigel Pharmaceuticals, Inc is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. | |
| General Information | |
| 1180 Veterans Boulevard
South San Francisc, CA 94080 |
|
| www.rigel.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 157 | |
| CEO: James M. Gower | |
| Short Interest | |
| Current Month (Mil) | 4.24 |
| Previous Month (Mil) | 3.99 |
| Short Interest Ratio (Days) | 2.70 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -35.80 |
| Return on Investments | -38.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |